公开(公告)号：US08673052B2

公开(公告)日：2014-03-18

申请号：US12818379

申请日：2010-06-18

申请人： Wenfeng Shi ,  Xueqing Chen ,  Yong Li ,  Xudong Xi ,  Tao Guo

发明人： Wenfeng Shi ,  Xueqing Chen ,  Yong Li ,  Xudong Xi ,  Tao Guo

IPC分类号： B22F9/20 ,  B22F1/00

CPC分类号： C01G35/00 ,  B22F9/20 ,  B22F2998/10 ,  B22F2999/00 ,  C01P2004/03 ,  C01P2004/62 ,  C01P2006/10 ,  C01P2006/12 ,  C01P2006/40 ,  H01G9/0029 ,  H01G9/0525 ,  B22F2201/013 ,  B22F2201/20 ,  B22F2201/10 ,  B22F1/0096

摘要： The present invention provides a process for preparing a tantalum powder with high specific capacity, which process comprising the steps of, in sequence, (1) a first reduction step: mixing tantalum oxide powder and a first reducing agent powder homogenously, and then carrying out reduction reaction in hydrogen and/or inert gas or vacuum atmosphere to obtain a tantalum suboxides powder; (2) a second reduction step: mixing the tantalum suboxides powder obtained from the step (1), in which impurities have been removed, and a second reducing agent powder homogenously, and then carrying out reduction reaction in hydrogen and/or inert gas or vacuum atmosphere to obtain a tantalum powder having high oxygen content; (3) a third reduction step: mixing the tantalum powder having high oxygen content obtained from the step (2), in which impurities have been removed, with a third reducing agent powder homogenously, and then carrying out reduction reaction in hydrogen and/or inert gas or vacuum atmosphere to obtain a tantalum metal powder suitable for capacitors; wherein after each reduction step, the oxidation product of reducing agent and the residual reducing agent are removed from the reaction product.

摘要翻译： 本发明提供一种制备高比容量的钽粉的方法，该方法包括以下步骤：（1）第一还原步骤：均匀混合氧化钽粉末和第一还原剂粉末，然后进行 在氢气和/或惰性气体或真空气氛中还原反应，得到低氧化钽粉末; （2）第二还原步骤：将其中除去杂质的步骤（1）获得的低密度氧化钡粉末和均质的第二还原剂粉末混合，然后在氢气和/或惰性气体中进行还原反应，或 真空气氛，得到氧含量高的钽粉末; （3）第三还原步骤：将已经除去杂质的步骤（2）获得的具有高氧含量的钽粉末与第三还原剂粉末均匀混合，然后在氢气和/或 惰性气体或真空气氛，得到适合电容器的钽金属粉末; 其中在每个还原步骤之后，从反应产物中除去还原剂和剩余还原剂的氧化产物。

公开(公告)号：US20100326239A1

公开(公告)日：2010-12-30

申请号：US12818379

申请日：2010-06-18

申请人： Wenfeng SHI ,  Xueqing Chen ,  Yong Li ,  Xudong Xi ,  Tao Guo

发明人： Wenfeng SHI ,  Xueqing Chen ,  Yong Li ,  Xudong Xi ,  Tao Guo

IPC分类号： B22F9/20 ,  B22F1/00

CPC分类号： C01G35/00 ,  B22F9/20 ,  B22F2998/10 ,  B22F2999/00 ,  C01P2004/03 ,  C01P2004/62 ,  C01P2006/10 ,  C01P2006/12 ,  C01P2006/40 ,  H01G9/0029 ,  H01G9/0525 ,  B22F2201/013 ,  B22F2201/20 ,  B22F2201/10 ,  B22F1/0096

摘要： The present invention provides a process for preparing a tantalum powder with high specific capacity, which process comprising the steps of, in sequence, (1) a first reduction step: mixing tantalum oxide powder and a first reducing agent powder homogenously, and then carrying out reduction reaction in hydrogen and/or inert gas or vacuum atmosphere to obtain a tantalum suboxides powder; (2) a second reduction step: mixing the tantalum suboxides powder obtained from the step (1), in which impurities have been removed, and a second reducing agent powder homogenously, and then carrying out reduction reaction in hydrogen and/or inert gas or vacuum atmosphere to obtain a tantalum powder having high oxygen content; (3) a third reduction step: mixing the tantalum powder having high oxygen content obtained from the step (2), in which impurities have been removed, with a third reducing agent powder homogenously, and then carrying out reduction reaction in hydrogen and/or inert gas or vacuum atmosphere to obtain a tantalum metal powder suitable for capacitors; wherein after each reduction step, the oxidation product of reducing agent and the residual reducing agent are removed from the reaction product.

摘要翻译： 本发明提供一种制备高比容量的钽粉的方法，该方法包括以下步骤：（1）第一还原步骤：均匀混合氧化钽粉末和第一还原剂粉末，然后进行 在氢气和/或惰性气体或真空气氛中还原反应，得到低氧化钽粉末; （2）第二还原步骤：将其中除去杂质的步骤（1）获得的低密度氧化钡粉末和均质的第二还原剂粉末混合，然后在氢气和/或惰性气体中进行还原反应，或 真空气氛，得到氧含量高的钽粉末; （3）第三还原步骤：将已经除去杂质的步骤（2）获得的具有高氧含量的钽粉末与第三还原剂粉末均匀混合，然后在氢气和/或 惰性气体或真空气氛，得到适合电容器的钽金属粉末; 其中在每个还原步骤之后，从反应产物中除去还原剂和剩余还原剂的氧化产物。

公开(公告)号：US20150361101A1

公开(公告)日：2015-12-17

申请号：US14766462

申请日：2014-02-03

申请人： Xing DAI ,  Anandan PALANI ,  Shuwen HE ,  Linda L. BROCKUNIER ,  Ravi NARGUND ,  Karen MARCANTONO ,  Nicolas Zorn ,  Dong XIAO ,  Xuanjia PENG ,  Tao GUO ,  MERCK SHARP & DOHME CORP.

发明人： Xing Dai ,  Hong Liu ,  Anandan Palani ,  Shuwen He ,  Linda L. Brockunier ,  Ravi Nargund ,  Karen Marcantonio ,  Nicolas Zorn ,  Dong Xiao ,  Xuanjia Peng ,  Peng Li ,  Tao Guo

IPC分类号： C07D519/00 ,  C07D471/14 ,  A61K31/4375 ,  A61K31/5025 ,  A61K31/438 ,  A61K31/55 ,  C07D471/22 ,  C07D471/04 ,  C07D471/20 ,  A61K45/06 ,  A61K31/519

CPC分类号： C07D519/00 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/55 ,  A61K45/06 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D471/22 ,  C07D487/14 ,  A61K2300/00

摘要： The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

摘要翻译： 本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5B聚合酶活性用于治疗或预防HCV感染的用途的式I化合物和 抑制基于细胞的系统中的HCV病毒复制和/或病毒生产。

公开(公告)号：US08691831B2

公开(公告)日：2014-04-08

申请号：US13416140

申请日：2012-03-09

申请人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voight ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John P. Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoxiang Liu ,  Tao Guo ,  Thuy X. E. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey A. Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

发明人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voight ,  Corey O. Strickland ,  Elizabeth M. Smith ,  Andrew W. Stamford ,  William J. Greenlee ,  Robert D. Mazzola, Jr. ,  John P. Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoxiang Liu ,  Tao Guo ,  Thuy X. E. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey A. Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

IPC分类号： A01N43/54 ,  A61K31/505

CPC分类号： C07D233/88 ,  A61K31/4168 ,  A61K31/4178 ,  C07D239/22 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D417/10 ,  C07D417/14 ,  C07D495/10

摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula I are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

摘要翻译： 公开了式I化合物或其立体异构体，互变异构体或其药学上可接受的盐或溶剂化物，其中式I中的每个变量如说明书中所定义; 以及包含式I化合物的药物组合物。还公开了抑制天冬氨酰蛋白酶的方法，特别是治疗心血管疾病，认知和神经退行性疾病的方法，以及抑制人类免疫缺陷病毒，plasmepins，组织蛋白酶D和 原生动物酶。 还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱m1激动剂或m2拮抗剂组合治疗认知或神经变性疾病的方法。

公开(公告)号：US08568090B2

公开(公告)日：2013-10-29

申请号：US12632152

申请日：2009-12-07

申请人： Tao Guo ,  Jonathon E. Slepski ,  Kenneth M. Koza

发明人： Tao Guo ,  Jonathon E. Slepski ,  Kenneth M. Koza

IPC分类号： F01D9/00

CPC分类号： F01D9/041 ,  F01D5/147 ,  F01D5/18 ,  F01D25/32 ,  F05D2220/31 ,  F05D2260/602

摘要： A system for removing moisture from a steam/water mixture engaging a stationary component of a steam turbine. The system includes an airfoil located within a flow path of a steam turbine. The airfoil is configured for removing moisture from a steam/water mixture traveling in the flow path. To this end, the airfoil includes a cavity in flow communication with the steam path through at least one inlet and outlet opening, near the leading and trailing edge of the airfoil, respectively. Moisture and steam are extracted from the surface through the inlet openings, the steam and water are separated in the cavity, the separated water flows towards the bottom end, and the dry steam flows through the outlet opening and returns to the steam path. The dry steam blowing out of the trailing edge reduces the size of secondary droplets, and thereby prevents erosion.

摘要翻译： 用于从与蒸汽轮机的固定部件接合的蒸汽/水混合物除去水分的系统。 该系统包括位于蒸汽轮机的流动路径内的翼型件。 翼型件构造成用于从在流动路径中行进的蒸汽/水混合物中除去水分。 为此，翼型件分别包括通过至少一个入口和出口开口与翼型件的前缘和后缘接近的与蒸汽通道流体连通的空腔。 水分和蒸汽通过入口从表面抽出，蒸汽和水在空腔中分离，分离的水流向底端，干蒸汽流过出口，返回到蒸汽通道。 从后缘吹出的干燥蒸汽减小二次液滴的尺寸，从而防止侵蚀。

公开(公告)号：US20130196974A1

公开(公告)日：2013-08-01

申请号：US13561366

申请日：2012-07-30

申请人： Li Chen ,  Lichun Feng ,  Song Feng ,  Lu Gao ,  Tao Guo ,  Mengwei Huang ,  Chungen Liang ,  Yongfu Liu ,  Lisha Wang ,  Jason Christopher Wong ,  Jim Zhen Wu ,  Xihan Wu ,  Hongying Yun ,  Xiufang Zheng

发明人： Li Chen ,  Lichun Feng ,  Song Feng ,  Lu Gao ,  Tao Guo ,  Mengwei Huang ,  Chungen Liang ,  Yongfu Liu ,  Lisha Wang ,  Jason Christopher Wong ,  Jim Zhen Wu ,  Xihan Wu ,  Hongying Yun ,  Xiufang Zheng

IPC分类号： C07D493/10 ,  C07D487/04 ,  C07D413/04 ,  C07D407/14 ,  C07D401/04 ,  C07D417/14 ,  C07D417/04

CPC分类号： C07D493/10 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D487/04 ,  C07D491/107

摘要： A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R10, A, Q, X and Y are as defined in the specification and claims, and their use as a pharmaceutical for the treatment or prophylaxis of respiratory syncytial virus disease.

摘要翻译： 式（I）化合物及其药学上可接受的盐，其中R 1至R 10，A，Q，X和Y如说明书和权利要求中所定义，及其作为治疗或预防呼吸道合胞体药物的用途 病毒病。

公开(公告)号：US08483425B2

公开(公告)日：2013-07-09

申请号：US12850816

申请日：2010-08-05

申请人： Tao Guo ,  Yoriko Kazama ,  Takashi Hino ,  Yoshiaki Kagawa

发明人： Tao Guo ,  Yoriko Kazama ,  Takashi Hino ,  Yoshiaki Kagawa

IPC分类号： G06K9/00

CPC分类号： G06K9/00637 ,  G06T7/12 ,  G06T7/73 ,  G06T17/05 ,  G06T2207/10032 ,  G06T2207/30184

摘要： To be precisely extracted a house footprint. There is provided a geospatial information creating system for extracting a footprint of a house from an aerial photograph, comprising a processor for executing a program, a memory for storing data required for executing the program, and a storage unit for storing the aerial photograph. The processor detects edges of an image based on a characteristic quantity of neighboring pixels in the aerial photograph stored in the storage unit; extracts an orientation of the house by analyzing directions of the detected edges; and generates a polygon of an outline of the house by using linear lines of the extracted orientation of the house.

摘要翻译： 准确提取房屋足迹。 提供了一种用于从空中照片提取房屋的占地面积的地理空间信息创建系统，包括用于执行程序的处理器，用于存储执行程序所需的数据的存储器和用于存储航空照片的存储单元。 处理器基于存储在存储单元中的空中照片中的相邻像素的特征量来检测图像的边缘; 通过分析检测到的边缘的方向来提取房屋的方位; 并且通过使用所提取的房屋取向的线性线来生成房屋的轮廓的多边形。

公开(公告)号：US08433526B2

公开(公告)日：2013-04-30

申请号：US12945680

申请日：2010-11-12

申请人： Binayak Roy ,  Tao Guo

发明人： Binayak Roy ,  Tao Guo

IPC分类号： G06F19/00

CPC分类号： G01N15/0205 ,  F01D21/003 ,  F22B35/16 ,  G01N21/534

摘要： A method of determining a steam quality of a wet steam located in an interior of a steam turbine includes emitting from an optical probe a plurality of wavelengths through the wet steam, measuring with the optical probe a wet steam intensity corresponding to each of the plurality of wavelengths emitted through the wet steam, determining an intensity ratio vector by dividing the wet steam intensity by a corresponding dry steam intensity for each of the plurality of wavelengths, successively applying scaling factors to the intensity ratio vector to obtain a scaled intensity ratio vector, calculating a suitable value for each of the scaling factors to obtain a plurality of residuals, determining a minimum residual of the plurality of residuals, determining a droplet size distribution by calculating the droplet number density corresponding to the minimum residual, and determining the steam quality based on the droplet size distribution.

摘要翻译： 确定位于蒸汽涡轮机内部的湿蒸汽的蒸汽质量的方法包括通过湿蒸汽从光学探针发射多个波长，用光学探针测量与多个 通过湿蒸汽发射的波长，通过将湿蒸汽强度除以对于多个波长中的每一个的相应的干蒸汽强度来确定强度比矢量，连续地将比例因子应用于强度比矢量，以获得比例的强度比矢量，计算 用于获得多个残差的每个缩放因子的合适值，确定多个残差的最小残差，通过计算对应于最小残差的液滴数密度来确定液滴尺寸分布，以及基于 液滴尺寸分布。

公开(公告)号：US20130018066A1

公开(公告)日：2013-01-17

申请号：US13551315

申请日：2012-07-17

申请人： Zhaoning Zhu ,  Brian A. McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voigt ,  Corey Strickland ,  Elizabeth M. Smith ,  Andrew Stamford ,  William J. Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy X.H. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse

发明人： Zhaoning Zhu ,  Brian A. McKittrick ,  Zhong-Yue Sun ,  Yuanzan C. Ye ,  Johannes H. Voigt ,  Corey Strickland ,  Elizabeth M. Smith ,  Andrew Stamford ,  William J. Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared N. Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy X.H. Le ,  Kurt W. Saionz ,  Suresh D. Babu ,  Rachael C. Hunter ,  Michelle L. Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse

IPC分类号： A61K31/4245 ,  A61P9/00 ,  A61P25/00 ,  C07D413/10 ,  A61P31/18 ,  A61P33/02 ,  A61K31/505 ,  C07D271/07 ,  A61K31/4439 ,  A61P25/28

CPC分类号： C07D233/46 ,  C07D233/70 ,  C07D233/88 ,  C07D239/22 ,  C07D239/70 ,  C07D271/07 ,  C07D273/00 ,  C07D401/04 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/08 ,  C07D403/10 ,  C07D403/12 ,  C07D405/10 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/06

摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

公开(公告)号：US08278334B2

公开(公告)日：2012-10-02

申请号：US12641952

申请日：2009-12-18

申请人： Jared N. Cumming ,  Ulrich Iserloh ,  Andrew Stamford ,  Corey Strickland ,  Johannes H. Voigt ,  Yusheng Wu ,  Ying Huang ,  Yan Xia ,  Samuel Chackalamannil ,  Tao Guo ,  Douglas W. Hobbs ,  Thuy X. H. Le ,  Jeffrey F. Lowrie ,  Kurt W. Saionz ,  Suresh D. Babu

发明人： Jared N. Cumming ,  Ulrich Iserloh ,  Andrew Stamford ,  Corey Strickland ,  Johannes H. Voigt ,  Yusheng Wu ,  Ying Huang ,  Yan Xia ,  Samuel Chackalamannil ,  Tao Guo ,  Douglas W. Hobbs ,  Thuy X. H. Le ,  Jeffrey F. Lowrie ,  Kurt W. Saionz ,  Suresh D. Babu

IPC分类号： A61K31/4439 ,  A61K31/40 ,  A61K31/4025 ,  C07D207/12 ,  C07D401/06 ,  C07D403/12

CPC分类号： C07D243/08 ,  C07D205/04 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/26 ,  C07D209/52 ,  C07D211/26 ,  C07D211/46 ,  C07D217/18 ,  C07D233/32 ,  C07D241/04 ,  C07D241/08 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06

摘要： Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

摘要翻译： 公开了下式的化合物或其药学上可接受的盐或溶剂化物，其中R1是R是-C（O）-N（R27）（R28），或其余的变量如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的药物组合物和方法，其包含式I化合物与除式I以外的分泌抑制剂抑制剂，HMG-CoA还原酶抑制剂，γ-分泌酶抑制剂，非 - 甾族抗炎药，N-甲基-D-天冬氨酸受体拮抗剂，胆碱酯酶抑制剂或抗淀粉样蛋白抗体。